Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a collaboration agreement with a National Institute on Aging (NIA)-sponsored study called the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI). This agreement enables the consortium to use MK-6240, Lantheus’ clinical-stage F18-labeled Positron Emission Tomography (PET) imaging agent, in its investigation of Alzheimer’s disease and related dementias. MK-6240 targets aggregated tau protein in the form of neurofibrillary tangles (NFTs) which are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
- This agreement enables the consortium to use MK-6240, Lantheus’ clinical-stage F18-labeled Positron Emission Tomography (PET) imaging agent, in its investigation of Alzheimer’s disease and related dementias.
- MK-6240 targets aggregated tau protein in the form of neurofibrillary tangles (NFTs) which are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
- “We are thrilled to partner with Lantheus to use MK-6240 for tau PET imaging in this important study.”
“MK-6240 is poised to play a pivotal role in propelling Alzheimer’s diagnosis and treatment research to new heights,” said Jean-Claude Provost, MD, Chief Medical Officer, Lantheus. - “This agreement aligns with Lantheus’ purpose to actively cultivate collaborations that empower researchers worldwide with essential tools to accelerate clinical research and development of therapies.